EA201490302A1 - Вводимые внутрибрюшинно наноносители, высвобождающие терапевтическую нагрузку в зависимости от воспалительной среды раковых опухолей - Google Patents

Вводимые внутрибрюшинно наноносители, высвобождающие терапевтическую нагрузку в зависимости от воспалительной среды раковых опухолей

Info

Publication number
EA201490302A1
EA201490302A1 EA201490302A EA201490302A EA201490302A1 EA 201490302 A1 EA201490302 A1 EA 201490302A1 EA 201490302 A EA201490302 A EA 201490302A EA 201490302 A EA201490302 A EA 201490302A EA 201490302 A1 EA201490302 A1 EA 201490302A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nanocarriers
intrainable
carriers
cancer tumor
inflammatory environment
Prior art date
Application number
EA201490302A
Other languages
English (en)
Russian (ru)
Inventor
Реема Зайнельден
Original Assignee
Стс. Юнм
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стс. Юнм filed Critical Стс. Юнм
Publication of EA201490302A1 publication Critical patent/EA201490302A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/911—Cancer cell destruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201490302A 2011-07-19 2012-07-18 Вводимые внутрибрюшинно наноносители, высвобождающие терапевтическую нагрузку в зависимости от воспалительной среды раковых опухолей EA201490302A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509251P 2011-07-19 2011-07-19
PCT/US2012/047133 WO2013012891A1 (en) 2011-07-19 2012-07-18 Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers

Publications (1)

Publication Number Publication Date
EA201490302A1 true EA201490302A1 (ru) 2014-07-30

Family

ID=47558435

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490302A EA201490302A1 (ru) 2011-07-19 2012-07-18 Вводимые внутрибрюшинно наноносители, высвобождающие терапевтическую нагрузку в зависимости от воспалительной среды раковых опухолей

Country Status (9)

Country Link
US (1) US9532949B2 (https=)
EP (1) EP2734191A4 (https=)
JP (1) JP2014523444A (https=)
CN (1) CN103917224A (https=)
AU (1) AU2012284147A1 (https=)
BR (1) BR112014001346A8 (https=)
CA (1) CA2842306A1 (https=)
EA (1) EA201490302A1 (https=)
WO (1) WO2013012891A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993437B2 (en) 2007-12-06 2018-06-12 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
ES2593027T3 (es) 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
US8992984B1 (en) 2009-10-21 2015-03-31 Stc.Unm Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
US20120207795A1 (en) 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
AU2012249474A1 (en) 2011-04-28 2013-11-07 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
US10220004B2 (en) 2011-07-14 2019-03-05 The Regents Of The University Of California Method of controlled delivery using sub-micron-scale machines
BR112014001346A8 (pt) 2011-07-19 2018-05-08 Stc Unm composto nanotransportador, método, composto farmacêutico e uso de um composto
US9687569B2 (en) 2012-08-16 2017-06-27 University Of Washington Through Its Center For Commercialization Theranostic nanoparticle and methods for making and using the nanoparticle
EP4378461A3 (en) * 2013-03-05 2024-09-11 The Regents of University of California Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
CN103611172B (zh) * 2013-12-02 2015-06-03 东南大学 载纳米雄黄磁性白蛋白纳米球及制备方法
CN103919803B (zh) * 2014-04-16 2018-07-31 厦门大学 一种装载砷剂的抗癌纳米药物及其制备方法
WO2016044716A1 (en) * 2014-09-19 2016-03-24 The American University In Cairo Nanoparticle-based combinatorial therapy
CN107921005A (zh) * 2015-02-13 2018-04-17 友杏生技医药股份有限公司 利用纳米颗粒治疗肿瘤的组合物和方法
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
JP2018530623A (ja) * 2015-10-15 2018-10-18 リポメディックス・ファーマシューティカルズ・リミテッドＬｉｐｏｍｅｄｉｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物
US20180369422A1 (en) * 2015-12-31 2018-12-27 City Of Hope Nanoparticles for cancer detection
US11672866B2 (en) 2016-01-08 2023-06-13 Paul N. DURFEE Osteotropic nanoparticles for prevention or treatment of bone metastases
CN108601746B (zh) 2016-01-08 2024-09-13 加利福尼亚大学董事会 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒
US12029724B2 (en) * 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
CN107362142B (zh) * 2016-05-13 2023-04-25 山东新时代药业有限公司 一种氟维司群脂质体注射液及其制备方法
JP7549306B2 (ja) * 2016-07-22 2024-09-11 株式会社リピドームラボ 新規リン脂質およびその利用ならびにリン脂質分離測定法の開発
AU2017327392B9 (en) * 2016-09-13 2023-10-12 Tiziana Life Sciences Plc Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
CN106943378B (zh) * 2017-02-16 2020-09-15 上海交通大学 红细胞膜包封聚酯类载三氧化二砷纳米粒及其制备方法
WO2018160865A1 (en) 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
CN107096037B (zh) * 2017-04-11 2019-12-31 同济大学 一种酶促小分子自组装制备纳米凝胶的方法
CN107213479B (zh) * 2017-06-22 2018-12-28 苏州杰纳生物科技有限公司 一种包含过氧化氢酶的组合物及用途
CN108014094A (zh) * 2017-12-26 2018-05-11 厦门大学 一种含顺铂和砷剂的纳米药物及其制备方法
US12383499B2 (en) 2018-01-01 2025-08-12 The Regents Of The University Of California Scale up synthesis of silicasome nanocarriers
WO2019213270A1 (en) * 2018-05-01 2019-11-07 Rutgers, The State University Of New Jersey Benzalkonium-embedded mesostructured silica compositions and uses of same
WO2020068798A1 (en) 2018-09-24 2020-04-02 Guo Jimin Living mammalian cells modified with functional modular nanoparticles
MX2021005110A (es) * 2018-11-02 2021-08-24 Tesorx Pharma Llc Quimioterapia intraperitoneal mejorada con liposomas.
TR201820952A2 (tr) * 2018-12-28 2020-07-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Granülosi̇t koloni̇ uyarici faktör i̇çeren bi̇r kombi̇nasyon
US12208164B2 (en) 2019-02-28 2025-01-28 Unm Rainforest Innovations Modular metal-organic polyhedra superassembly compositions
US11207348B2 (en) 2019-04-25 2021-12-28 Imam Abdulrahman Bin Faisal University Spinel ferrite impregnated mesoporous silica containing a platinum complex
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN110448541B (zh) * 2019-08-02 2021-10-01 中山大学 双功能化纳米粒、可溶性微针及其制备方法与应用
CN114686416B (zh) * 2020-12-30 2024-03-19 湖南大学 一种膜融合脂质体及其应用
US11779652B2 (en) 2021-06-18 2023-10-10 Imam Abdulrahman Bin Faisal University Porous silicate/magnetic ferrite nanocarrier for combination anti-cancer therapeutic and antioxidant delivery
CN114031048B (zh) * 2021-11-09 2024-03-15 广州天科生物科技有限公司 一种纳米硒的制备方法
CN115089728B (zh) * 2022-06-16 2024-01-26 磐如生物科技(天津)有限公司 一种膀胱癌靶向纳米药物及其制备方法
CN115105584B (zh) * 2022-06-28 2023-03-31 长春生物制品研究所有限责任公司 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5277913A (en) 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
US5820879A (en) * 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
ATE209887T1 (de) * 1993-04-02 2001-12-15 Anticancer Inc Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6264741B1 (en) 1998-11-25 2001-07-24 Sandia Corporation Self-assembly of nanocomposite materials
US6350464B1 (en) * 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
WO2003016040A1 (en) 2001-04-16 2003-02-27 The Regents Of The University Of California Membrane mimetic architectures on nanoporous materials
US20060177495A1 (en) 2001-12-21 2006-08-10 Christine Allen Polymer-lipid delivery vehicles
US20040005352A1 (en) 2002-04-16 2004-01-08 Lopez Gabriel P. Biologically functionalized porous microspheres
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
US20070037751A1 (en) * 2003-08-06 2007-02-15 Gastrotech Pharma A/S Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
KR20070110084A (ko) 2005-02-14 2007-11-15 오스트레일리언뉴클리어사이언스앤드테크놀로지오거나이제이션 층상 나노입자
US7514267B1 (en) 2005-08-19 2009-04-07 Stcunm Detection systems utilizing supported lipid bilayers
US20080160313A1 (en) 2006-04-26 2008-07-03 Gabriel Lopez Lipid bilayers on nanotextured solid surfaces
MX2009001533A (es) * 2006-08-11 2009-02-18 Panacea Biotec Ltd Particulas para el suministro de ingredientes activos, procedimiento de elaboracion y sus composiciones.
EP2099496A2 (en) 2006-12-08 2009-09-16 Massachusetts Institute of Technology Delivery of nanoparticles and/or agents to cells
US20080279764A1 (en) * 2007-03-09 2008-11-13 Anthony Manganaro Method and composition for treating cancer
CA2702103A1 (en) 2007-10-12 2009-04-16 Novosom Ag Improvements in or relating to amphotaric liposomes comprising neutral lipids
US9993437B2 (en) 2007-12-06 2018-06-12 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
US20110105995A1 (en) * 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
US8962344B2 (en) 2008-03-16 2015-02-24 Synamem Corporation Membrane-coated particles
CA2722183C (en) 2008-04-25 2018-09-18 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
JP5366612B2 (ja) 2008-05-20 2013-12-11 株式会社東芝 画像処理装置、画像処理方法および画像処理プログラム
CN101658533A (zh) 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
WO2010078569A2 (en) 2009-01-05 2010-07-08 Stc.Unm Porous nanoparticle supported lipid bilayer nanostructures
US8992984B1 (en) 2009-10-21 2015-03-31 Stc.Unm Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
US20130017210A1 (en) 2010-03-17 2013-01-17 Stc.Unm Display of antibody fragments on virus-like particles of rna bacteriophages
US20110300186A1 (en) 2010-04-14 2011-12-08 Battelle Memorial Institute Functionalized Nano- and Micro-materials for Medical Therapies
AU2012249474A1 (en) 2011-04-28 2013-11-07 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
BR112014001346A8 (pt) 2011-07-19 2018-05-08 Stc Unm composto nanotransportador, método, composto farmacêutico e uso de um composto
JP2014532071A (ja) 2011-10-14 2014-12-04 エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法
WO2013103614A1 (en) 2011-12-30 2013-07-11 Stc.Unm Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all)
US20160151482A1 (en) 2013-04-02 2016-06-02 Stc. Unm Mesoporous alum nanoparticles as a universal platform for antigen adsorption, presentation, and delivery
WO2014165608A1 (en) 2013-04-02 2014-10-09 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
EP3046543A1 (en) 2013-09-18 2016-07-27 Stc.Unm Torroidal mesoporous silica nanoparticles (tmsnps) and related protocells
WO2015042268A1 (en) 2013-09-18 2015-03-26 Stc.Unm Core and surface modification of mesoporous silica nanoparticles to achieve cell specific targeting in vivo

Also Published As

Publication number Publication date
CA2842306A1 (en) 2013-01-24
EP2734191A1 (en) 2014-05-28
US9532949B2 (en) 2017-01-03
CN103917224A (zh) 2014-07-09
BR112014001346A2 (pt) 2017-07-18
WO2013012891A1 (en) 2013-01-24
JP2014523444A (ja) 2014-09-11
US20140212479A1 (en) 2014-07-31
BR112014001346A8 (pt) 2018-05-08
EP2734191A4 (en) 2015-04-29
AU2012284147A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
EA201490302A1 (ru) Вводимые внутрибрюшинно наноносители, высвобождающие терапевтическую нагрузку в зависимости от воспалительной среды раковых опухолей
Lammers Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations
Liu et al. pH-sensitive nano-systems for drug delivery in cancer therapy
Lozada-Delgado et al. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials
JP2011079858A5 (https=)
MX369106B (es) Anticuerpo anti trop-2 humano que tiene actividad anti-tumoral in vivo.
NI201200181A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
NZ703047A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
EA201590847A1 (ru) Новые ингибиторы rock
JP2014506233A5 (https=)
EA201300145A1 (ru) Пептид для применения в лечении рака молочной железы и/или метастазов в кости
EA201891575A1 (ru) Составы для лечения рака мочевого пузыря
Ma et al. Crucial role of heme oxygenase-1 in the sensitivity of acute myeloid leukemia cell line Kasumi-1 to ursolic acid
ECSP11011552A (es) Administracion continua de cilengitida en tratamientos contra el cancer
Gupta et al. Recent advances in targeted nanotherapeutic approaches for breast cancer management
PH12018501339A1 (en) Combination therapy
Peng et al. Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2′-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
ES2980236T3 (es) Combinación de AS1411 y SAPC-DOPS para el tratamiento de glioblastoma multiforme
MX2015006096A (es) Leucocitos como celulas de administracion para imagen y terapia de enfermedad.
JP2015524441A5 (https=)
EA202190565A1 (ru) Пеллеты с многослойной структурой для замедленного высвобождения действующего вещества в дистальных отделах толстой кишки
JP2015529664A5 (https=)